SNRPB was found to be upregulated in ovarian cancer cells, promoted tumor growth, supported canonical BRCA2 splicing, and suppressed aberrant exon 3 skipping, thereby affecting the response to cisplatin. The gene discussed is BRCA2; the disease is ovarian cancer.